A Study of Baricitinib in Participants With Rheumatoid Arthritis

Prior treatment

• Participant must not have prior use of a Janus kinase (JAK) inhibitor or have received more than 1 prior TNF inhibitor that was:
  • discontinued for lack or loss of efficacy for RA, or
  • discontinued for intolerance (AE) when used for any indication
• Participants must not have had a live vaccine within four weeks of study start

Other illness

• Participants must not have cancer
• Participants must not have active herpes zoster, serious infection, active tuberculosis, or any other serious illness
• Participants must not have a history of IV drug use, other illicit drug abuse, or chronic alcohol abuse in the past year

Other

• Participants must not be pregnant or breastfeeding
• Participants must not have had more than one VTE
• Participants must not have participated in any other clinical trial within four weeks of study start

• Participants must have at least one of the following characteristics:
  • Documented evidence of a VTE prior to this study
  • At least 60 years of age
  • A body mass index (BMI) greater than or equal to 30 kilograms per meter squared (kg/m²), or
  • Age 50 to less than 60 years and BMI 25 to less than 30 kg/m²
• Participants must have an inadequate response or intolerance to at least 1 disease-modifying antirheumatic drug (DMARD) (synthetic or biologic)